Kidney Outcomes With SGLT-2 Inhibitors

Abstract

Get full access to this article

View all access options for this article.

References

Amereican Diabetes Association. 11. Microvascular complications and foot care: standards of medical care in diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S135-S151.

Alicic

Rooney

Tuttle

KR.

Diabetic kidney disease. Clin J Am Soc Nephrol. 2017;12(12):2032-2045.

Górriz

Navarro-González

Ortiz

, et al. Sodium-glucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease. Nephrol Dial Transplant. 2020;35(suppl 1):i13-i23.

Neal

Perkovic

Mahaffey

, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644-657.

Wiviott

Raz

Bonaca

, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347-357.

Zinman

Wanner

Lachin

, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128.

Wanner

Inzucchi

Zinman

Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(18):1801-1802.

AstaZeneca. Farxiga Phase III DAPA-CKD trial will be stopped early after overwhelming efficacy in patients with chronic kidney disease. Published 2020. Accessed January 5, 2020. https://www.astrazeneca.com/media-centre/press-releases/2020/farxiga-phase-iii-dapa-ckd-trial-will-be-stopped-early-after-overwhelming-efficacy-in-patients-with-chronic-kidney-disease.html

Perkovic

Jardine

Neal

, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295-2306.

10.

Kumbhani

. Evaluation of ertugliflozin efficacy and safety cardiovascular outcomes trial - VERTIS CV. Accessed January 9, 2020. https://www.acc.org/latest-in-cardiology/clinical-trials/2020/06/16/11/24/vertis

11.

Zelniker

Wiviott

Raz

, et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation. 2019;139(17):2022-2031.

12.

Zelniker

Wiviott

Raz

, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet (London, England). 2019;393(10166):31-39.